Prospects for the treatment of Parkinson's disease using neurotrophic factors

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 10, 2001, Pages 1531-1543

  Hurelbrink, C B ^a   Barker, R A ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Animal models; Glial cell line derived neurotrophic factor; Growth factor; Transforming growth factor

Indexed keywords

4 AMINOBUTYRIC ACID; ACIDIC FIBROBLAST GROWTH FACTOR; ALPHA SYNUCLEIN; ARTEMIN; BASIC FIBROBLAST GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; DOPAMINE; EPIDERMAL GROWTH FACTOR; GANGLIOSIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH DIFFERENTIATION FACTOR 15; GROWTH DIFFERENTIATION FACTOR 5; INTERLEUKIN 1; INTERLEUKIN 6; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN; NEURTURIN; PERSEPHIN; PLATELET DERIVED GROWTH FACTOR; SEROTONIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN GRAFT; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENCAPSULATION; HUMAN; LENTIVIRINAE; MOUSE; NERVE CELL NECROSIS; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT; REVIEW; SYMPTOM;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0034758936     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.10.1531     Document Type: Review

References (148)

1. Prospects for the treatment of Parkinson's disease using neural grafts
2. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
3. Neurotrophic molecules
4. Neurotrophic factors and neural grafts: A growing field
5. Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease
6. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease
7. Improving the survival of grafted dopaminergic neurons: A review over current approaches
8. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons
9. Improved survival of embryonic porcine dopaminergic neurons in coculture with a conditionally immortalized GDNF-producing hippocampal cell line
10. Effects of combined BDNF and GDNF treatment on cultured dopaminergic midbrain neurons
11. GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro
12. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium
13. GDNF reduces apoptosis in dopaminergic neurons in vitro
14. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture
15. GDNF and NT-4 protect midbrain dopaminergic neurons from toxic damage by iron and nitric oxide
16. Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro
17. Glial cell line derived neurotrophic factor promotes the recovery of dopamine neurons damaged by 6-hydroxydopamine in vitro
18. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons
19. Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants
20. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle
21. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons
22. Persephin, a novel neurotrophic factor related to GDNF and neurturin
23. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: Neuroprotective strategies
24. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system
25. A quantitative study of cell death in the substantia nigra following a mechanical lesion of the medial forebrain bundle
26. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
27. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo
28. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain
29. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons
30. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease
31. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats
32. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease
33. Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system
34. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: Behavioral and histological studies using two different dosages
35. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats
36. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
37. GDNF protects against 6-OHDA nigrostriatal lesion: In vivo study with microdialysis and PET
38. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine
39. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: Comparison of intraventricular delivery
40. GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration
41. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model
42. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor
43. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo
44. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
45. Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice
46. GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice
47. Functional recovery in parkinsonian monkeys treated with GDNF
48. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys
49. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys
50. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys
51. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease
52. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms
53. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine
54. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell factor
55. Dopaminergic neurons protected from degeneration by GDNF gene therapy
56. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor
57. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease
58. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat
59. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections
60. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease
61. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain
62. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease
63. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
64. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system
65. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease
66. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin
67. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF
68. Clinical observations after neural transplantation in Parkinson's disease
69. Development of fetal neural transplantation as a treatment for Parkinson's disease
70. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts
71. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
72. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo
73. Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo
74. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts
75. GDNF partially protects grafted fetal dopaminergic neurons against 6-hydroxydopamine neurotoxicity
76. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats
77. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats
78. Transplantation in the rat model of Parkinson's disease: Ectopic versus homotopic graft placement
79. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease
80. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum
81. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats
82. Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor
83. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease
84. Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line-derived neurotrophic factor
85. A glial cell line-derived neurotrophic factor-secreting clone of the Schwann cell line SCTM41 enhances survival and fiber outgrowth from embryonic nigral neurons grafted to the striatum and to the lesioned substantia nigra
86. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue
87. The effects of storage conditions and trophic supplementation on the survival of fetal mesencephalic cells
88. Preservation of fetal ventral mesencephalic cells by cool storage: In-vitro viability and TH-positive neuron survival after microtransplantation to the striatum
89. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease
90. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts
91. Human cadaver embryonic substantia nigra grafts: Ontogeny, preoperative graft preparation and tissue storage
92. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. cases and technical considerations
93. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells
94. Grafting of nigral tissue hibernated with tirilazad mesylate and glial cell line-derived neurotrophic factor
95. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3
96. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
97. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos
98. Rat fetal ventral mesencephalon grown as solid tissue cultures: Influence of culture time and BDNF treatment on dopamine neuron survival and function
99. Effects of donor age and brain-derived neurotrophic factor on the survival of dopaminergic neurons and axonal growth in postnatal rat nigrostriatal cocultures
100. The survival response of mesencephalic dopaminergic neurons to the neurotrophins BDNF and NT-4 requires priming with serum: Comparison with members of the TGF-beta superfamily and characterization of the serum-free culture system
101. Effects of BDNF on dopaminergic, serotonergic, and GABAergic neurons in cultures of human fetal ventral mesencephalon
102. The response of human and rat fetal ventral mesencephalon in culture to the brain-derived neurotrophic factor treatment
103. Ganglioside GM1 cooperates with brain-derived neurotrophic factor to protect dopaminergic neurons from 6-hydroxydopamine-induced degeneration
104. Brain-derived neurotrophic factor selectively rescues mesencephalic dopaminergic neurons from 2,4,5-trihydroxyphenylalanine-induced injury
105. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system
106. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon
107. Convergent regulation by ciliary neurotrophic factor and dopamine of tyrosine hydroxylase expression in cultures of rat substantia nigra
108. Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP(+)-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF
109. Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic CNS neurons: Comparison with basic fibroblast growth factor
110. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia
111. Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture
112. Mitogenic effect of basic fibroblast growth factor on embryonic ventral mesencephalic dopaminergic neurone precursors
113. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons--I. Effects in vitro
114. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: Involvement of the glutathione system
115. Development of dopaminergic neurons in the human mesencephalon and in vitro effects of basic fibroblast growth factor treatment
116. Growth/Differentiation factor-15/Macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons In vivo
117. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons
118. Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures: II. Modulatory effects of gangliosides
119. Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons
120. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures
121. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II
122. Comparison of the effects of the neurotrophins on the morphological structure of dopaminergic neurons in cultures of rat substantia nigra
123. Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures
124. Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture
125. Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in vitro
126. Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture
127. Trophic actions of transforming growth factor alpha on mesencephalic dopaminergic neurons developing in culture
128. TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity
129. TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons
130. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease
131. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat
132. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo
133. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer
134. GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse
135. Ganglioside treatment in the recovery of the DA nigrostriatal system in different experimental conditions
136. Further studies on the effects of the GM1 ganglioside on the degenerative and regenerative features of mesostriatal dopamine neurons
137. Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting
138. Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease
139. BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons
140. Brain-derived neurotrophic factor enhances function rather than survival of intrastriatal dopamine cell-rich grafts
141. Basic fibroblast growth factor ameliorates rotational behavior of substantia nigral-transplanted rats with lesions of the dopaminergic nigrostriatal neurons
142. Basic fibroblast growth factor enhances survival and sprouting of fetal dopaminergic cells implanted in the denervated rat caudate-putamen: Preliminary observations
143. Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation
144. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease
145. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons--II. Effects on nigral transplants in vivo
146. In vivo effects of kFGF on embryonic nigral grafts in a rat model of Parkinson's disease
147. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease
148. Differential effects of platelet-derived growth factor isoforms on dopamine neurons in vivo: -BB supports cell survival, -AA enhances fiber formation